Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
NRIX security holder Johannes Van Houte has filed to sell common stock under Rule 144. The filing lists 4,761 common shares to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate value of $110,550.42. These shares are tied to Restricted Stock Units dated July 30, 2026.
The filing also reports prior sales in the last three months: 2,845 common shares sold on July 30, 2026 for $66,524.07, and 14,055 common shares sold on May 5, 2026 for $233,319.27, identified as 10b5-1 sales for Johannes Van Houte.
Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised employee stock options for 5,787 shares of common stock at an exercise price of $8.72 per share and, on the same date, sold 16,589 common shares at a weighted average price of $23.0489 (within a $22.67–$23.30 range). Following the option exercise, 122,824 stock options tied to common stock remain outstanding, expiring in 2034. These transactions were effected under a previously adopted Rule 10b5-1 trading plan.
Nurix Therapeutics, Inc. (NRIX) reports that insider Christine Ring has filed to sell up to 16,589 shares of common stock, with an aggregate market value of $385,030.69, through Morgan Stanley Smith Barney LLC, with sales expected on or after August 3, 2026 on NASDAQ. The shares derive from an exercise of stock options for 5,787 shares on August 3, 2026 for cash and 10,802 restricted stock units vesting on July 30, 2025. The filing also lists prior Rule 10b5-1 sales over the past three months, including a sale of 28,935 shares for $580,506.12 on June 25, 2026, along with several smaller transactions.
Vanguard Capital Management LLC and certain affiliates report beneficial ownership of 5,202,025 shares of Nurix Therapeutics Inc. common stock, representing 5.03% of the class as of June 30, 2026.
Vanguard has sole voting power over 706,496 shares and sole dispositive power over all 5,202,025 shares, with no shared voting or dispositive power. The position reflects securities held by Vanguard funds and managed accounts over which Vanguard entities exercise voting and/or dispositive authority, and no other individual person's interest exceeds 5% of the class.
Nurix Therapeutics, Inc. reported that CFO Hans van Houte exercised three tranches of restricted stock units, converting 10,180 RSUs into the same number of common shares at a $0 exercise price. He then sold 2,845 shares at a weighted average price of $23.3828, within a $23.00–$23.90 range, solely to cover RSU-related tax withholding under a mandatory “sell to cover” arrangement, rather than as discretionary trades.
Nurix Therapeutics, Inc. reported insider activity by Chief Legal Officer Christine Ring on July 30, 2026. Three RSU tranches of 3,750, 2,858, and 3,572 units (total 10,180) vested and converted into the same number of common shares at a $0.00 exercise price. On the same date, 3,847 common shares were sold at a weighted average price of $23.3828 per share to cover tax withholding obligations through a mandatory “sell to cover” mechanism under the issuer’s equity plans, and the filing notes these were not discretionary trades.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported the vesting and conversion of 10,180 Restricted Stock Units into an equal number of shares of common stock on July 30, 2026, at an exercise price of $0.00 per share.
On the same date, Hansen sold 3,847 shares of common stock at a weighted average price of $23.3828 per share, within a range of $23.00 to $23.90. According to the disclosure, these shares were sold solely to cover tax withholding obligations under the company’s equity incentive plans through a mandated "sell to cover" transaction and were not discretionary trades.
Nurix Therapeutics reported another period of heavy investment as it advances its protein degradation pipeline, with a net loss of $176.7 million for the six months ended May 31, 2026, compared with $99.8 million a year earlier.
Total revenue fell to $15.3 million from $62.5 million, mainly due to the absence of prior-period license revenue, while research and development spending rose to $171.8 million as clinical programs for bexobrutideg, zelebrudomide and NX‑1607 progressed.
The company ended the quarter with $443.5 million in cash, cash equivalents and marketable securities and 103.7 million shares outstanding. After quarter‑end, Nurix signed a global collaboration with Roche for bexobrutideg, including a $700 million upfront payment and potential milestones bringing total payments up to $2.3 billion.
Nurix Therapeutics reported fiscal second-quarter 2026 results and unveiled a major global collaboration with Roche for its BTK degrader bexobrutideg.
Revenue was $9.0 million for the quarter ended May 31, 2026, down from $44.1 million a year earlier, mainly because the prior period included $30 million of one-time Sanofi license revenue. Research and development expenses rose to $87.7 million, reflecting higher clinical and manufacturing spend, and net loss widened to $89.5 million, or $0.81 per share.
Nurix ended the quarter with $443.5 million in cash, cash equivalents and marketable securities and cites pro-forma cash of about $1.14 billion, including an expected $700 million upfront payment from Roche. The Roche alliance provides potential total payments of up to $2.3 billion tied to bexobrutideg’s development and commercialization.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an option exercise-and-sale transaction in company stock. She exercised employee stock options to acquire a total of 11,008 shares of common stock at exercise prices of $8.72 and $1.86 per share, then sold 11,008 shares in an open-market sale at a weighted average price of $23.5616 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds 13,579 shares of common stock and retains an employee stock option covering 128,611 shares at an exercise price of $8.72 per share, expiring on February 12, 2034.